Martha Catalina Rivera Cervantes

Dr. Martha Catalina Rivera Cervantes


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
VCVeronica Chaparro-Huerta
Veronica Chaparro-Huerta
MCMartha Catalina Rivera Cervantes
Martha Catalina Rivera Cervantes
MFM.E. Flores-Soto
M.E. Flores-Soto
UGU. Gómez-Pinedo
U. Gómez-Pinedo
CBC. Beas-Zárate
C. Beas-Zárate

7 February 2018 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JJJosé Jarero-Basulto
José Jarero-Basulto
YGYadira Gasca-Martínez
Yadira Gasca-Martínez
MCMartha Catalina Rivera Cervantes
Martha Catalina Rivera Cervantes
MUMónica E. Ureña-Guerrero
Mónica E. Ureña-Guerrero
AFAlfredo I. Feria-Velasco
Alfredo I. Feria-Velasco
CBCarlos Beas-Zarate
Carlos Beas-Zarate
Undoubtedly, one of the most interesting topics in the field of neuroscience is the ability of the central nervous system to respond to different stimuli (normal or pathological) by modifying its structure and function, either transiently or permanently, by generating neural cells and new connections in a process known as neuroplasticity. According to the large amount of evidence reported in the literature, many stimuli, such as environmental pressures, changes in the internal dynamic steady state of the organism and even injuries or illnesses (e.g., epilepsy) may induce neuroplasticity. Epilepsy and neuroplasticity seem to be closely related, as the two processes could positively affect one another. Thus, in this review, we analysed some neuroplastic changes triggered in the hippocampus in response to seizure-induced neuronal damage and how these changes could lead to the establishment of temporal lobe epilepsy, the most common type of focal human epilepsy.

6 May 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
MUMónica E. Ureña-Guerrero
Mónica E. Ureña-Guerrero
José Luis Castañeda-CabralJosé Luis Castañeda-Cabral
José Luis Castañeda-Cabral
MCMartha Catalina Rivera Cervantes
Martha Catalina Rivera Cervantes
RMRafael J. Macias-Velez
Rafael J. Macias-Velez
JJJosé Jarero-Basulto
José Jarero-Basulto
CBCarlos Beas-Zárate
Carlos Beas-Zárate
Background: Erythropoietin (Epo) and vascular endothelial growth factor (VEGF) are two vasoactive molecules with essential trophic effects for brain development. The expression and secretion of both molecules increase in response to neuronal damage and they exert protective and restorative effects, which may also be accompanied by adverse side effects.Objective: We review the most relevant evidence on the neuroprotective and neurorestorative effects of Epo and VEGF in three of the most frequent neurological disorders, namely, stroke, epilepsy and Alzheimer's disease, to develop new therapeutic approaches.Method: Several original scientific manuscripts and reviews that have discussed the evidence in critical way, considering both the beneficial and adverse effects of Epo and VEGF in the selected neurological disorders, were analysed. In addition, throughout this review, we propose several considerations to take into account in the design of therapeutic approaches based on Epo and VEGF signalling.Results: Although the three selected disorders are triggered by different mechanisms, they evolve through similar processes: excitotoxicity, oxidative stress, neuroinflammation, neuronal death, glial reactivity and vascular remodelling. Epo and VEGF exert neuroprotective and neurorestorative effects by acting on these processes due to their pleiotropism. In general, the evidence shows that both Epo and VEGF reduce neuronal death but that at the vascular level, their effects are contradictory.Conclusion: Because the Epo and VEGF signalling pathways are connected in several ways, we conclude that more experimental studies, primarily studies designed to thoroughly assess the functional interactions between Epo and VEGF in the brain under both physiological and pathophysiological conditions, are needed.

23 April 2004 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
MCMartha Catalina Rivera Cervantes
Martha Catalina Rivera Cervantes
JTJ. Segura Torres
J. Segura Torres
AFA. Feria‐Velasco
A. Feria‐Velasco
JAJ. Armendariz‐Borunda
J. Armendariz‐Borunda
CBC. Beas‐Zárate
C. Beas‐Zárate

5 November 2013 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
Daniel Ortuño-SahagúnDaniel Ortuño-Sahagún
Daniel Ortuño-Sahagún
RGRaúl Montes González
Raúl Montes González
EVEster Verdaguer
Ester Verdaguer
VHVerónica Chaparro Huerta
Verónica Chaparro Huerta
BTBlanca Miriam Torres-Mendoza
Blanca Miriam Torres-Mendoza
CZC. Beas Zárate
C. Beas Zárate

1 September 2013 in Neuroscience Letters
Verified
Journal Article
Closed access
JMJusto Murguía-Castillo
Justo Murguía-Castillo
CBCarlos Beas-Zárate
Carlos Beas-Zárate
MCMartha Catalina Rivera Cervantes
Martha Catalina Rivera Cervantes
AFAlfredo I. Feria-Velasco
Alfredo I. Feria-Velasco
MUMonica E. Ureña-Guerrero
Monica E. Ureña-Guerrero